Navigation Links
Rensselaer professors Dordick and Interrante named ACS Fellows
Date:10/4/2010

Troy, N.Y. Two Rensselaer Polytechnic Institute professors have been named 2010 fellows of the American Chemical Society (ACS). Director of the Center for Biotechnology and Interdisciplinary Studies (CBIS) and the Howard P. Isermann '42 Professor of Chemical and Biological Engineering Jonathan Dordick and Professor Emeritus of Chemistry Leonard Interrante were both recognized by the ACS for their "outstanding achievements in and contributions to the science, the profession, and service to the society."

"Both of these esteemed researchers and educators have had a major impact on their fields," said Rensselaer Provost Robert Palazzo. "Dr. Dordick is among the foremost biocatalysis and bioengineering experts in the world. His recent discovery of antibacterial coatings could protect thousands of people from harmful bacterial infections and his work to develop biochip technologies is transforming the way we view the modern drug discovery process.

"Dr. Interrante is both a polymer pioneer and successful entrepreneur. He has developed sophisticated new materials utilized in technologies around the world, including the Hubble Space Telescope. His pure silicon carbide-forming polymer is the only of its kind commercially available in the world, paving the way for an entirely new generation of high-temperature, high-strength ceramic composites."

The ACS honored the new fellows at the society's fall national meeting.

Dordick's research interests are in the areas of biocatalysis, bioengineering, and nanobiotechnology. He most recently developed a nanoscale coating for surgical equipment, hospital walls, and other surfaces that safely eradicates methicillin-resistant Staphylococcus aureus (MRSA). He has also discovered a biochip that could eliminate animal testing in the chemicals and cosmetics industries, and drastically curtail its use in the development of new pharmaceuticals. The co-founder of EnzyMed Inc., a pharmaceutical discovery company, he is currently a co-founder of Solidus Biosciences, a venture-stage biotechnology company. In addition, he serves on the scientific advisory boards for several biotechnology companies and has served as chair of the division of biochemical technology for the ACS.

Dordick joined the Rensselaer faculty in 1998. He became director of CBIS in 2008. He is a fellow of both the American Institute for Medical and Biological Engineering and the American Association for the Advancement of Science (AAAS).

Dordick received his doctorate in biochemical engineering in 1986 from the Massachusetts Institute of Technology.

Interrante's research encompasses a wide range of subjects in materials chemistry. His works spans the study of both inorganic and organic polymers to the development of new, advanced materials. His ceramic and ceramic composite materials have broad applications for aerospace, industrial, and energy generation applications. His development of the pure silicon carbide forming polymer enables the processing of high-temperature, high-strength ceramic composites. The polymer helped him co-found Starfire Systems Inc., a high-tech advanced materials manufacturer that started at Rensselaer. His research is utilized in areas from aerospace to motorcycles.

Interrante joined Rensselaer in 1985. He is founding and current editor-in-chief of the ACS journal Chemistry of Materials. Before coming to Rensselaer, Interrante spent 17 years at the General Electric Research and Development Center. He is a fellow of the AAAS and was named Inventor of the Year in 2007 by Eastern New York Intellectual Property Law Association.

Interrante received his doctorate in inorganic chemistry from the University of Illinois, Urbana-Champaign in 1963.


'/>"/>

Contact: Gabrielle DeMarco
demarg@rpi.edu
518-956-0701
Rensselaer Polytechnic Institute
Source:Eurekalert

Related biology news :

1. Trustee makes donation to start new solar energy research center at Rensselaer
2. Rensselaer receives more than $2 million from New York State to fund stem cell research
3. Rensselaer leads effort to replace 1 of the most widely used drugs in American hospitals
4. Rensselaer researchers to send bacteria into orbit aboard space shuttle Atlantis
5. Rensselaer Polytechnic Institute wins $2.45 million grant to support stem cell research
6. Rensselaer Polytechnic Institute professor Patrick Underhill receives NSF CAREER award
7. Rensselaer Polytechnic Institute professor Peter M. Tessier named Pew Scholar
8. Left or right? Early clues to soccer penalty kicks revealed at Rensselaer Polytechnic Institute
9. Rensselaer professor uncovers mysterious workings of cholera bacteria
10. Purifying proteins: Rensselaer researchers use NMR to improve drug development
11. National Science Foundation grants Clemson professors award to develop nanoprobes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
(Date:3/22/2016)... Ontario , PROVO and ... Newborn Screening Ontario (NSO), which operates the ... for molecular testing, and Tute Genomics and UNIConnect, ... management technology respectively, today announced the launch of a ... next-generation sequencing (NGS) testing panel. NSO ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology: